| Project/Area Number |
09672291
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
医薬分子機能学
|
|---|
| Research Institution | KOBE GAKUIN UNIVERSITY |
|---|
Principal Investigator |
KAWASAKI Koichi KOBE GAKUIN UNIVERSITY, FACULTY OF PHARMACEUTICAL SCIENCES, PROFESSOR, 教授 (40068242)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HOJO Keiko KOBE GAKUIN UNIVERSITY, FACULTY OF PHARMACEUTICAL SCIENCES, ASSISTANT, 実験助手 (20289028)
MAEDA Mitsuko KOBE GAKUIN UNIVERSITY, FACULTY OF PHARMACEUTICAL SCIENCEs, RESEACH ASSISTANT PROFESSOR, 助手 (90131531)
|
|---|
| Project Period (FY) |
1997 – 1999
|
| Project Status |
Completed (Fiscal Year 1999)
|
| Budget Amount *help |
¥3,100,000 (Direct Cost: ¥3,100,000)
Fiscal Year 1999: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 1998: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 1997: ¥1,300,000 (Direct Cost: ¥1,300,000)
|
|---|
| Keywords | POLY (ETHYLENE GLYCOL) / DRUG CARRIER / LAMININ / FIBRONECTIN / 癌転移 / 高分子担体 / 細胞接着タンパク質 |
|---|
| Research Abstract |
Since poly (ethylene glycol) (PEG) has a low toxicity, a low immunogenicity, and good solubility in both aqueous and organic solvents, it appears to be a promising drug-carrier. Many studies on pegylation of proteins have been reported, but few of them report on the pegylation of small peptides. We were successful in forming PEG hybrids of small peptides [such as RGD derived from fibronectin and YIGSR derived from laminin] that results in the potentiation of activity of the parent peptides. The two hydroxyl groups situated at each terminal of commercially available PEG are the functional group that can attach to two same peptides. We planned to prepare a multi-functional PEG-peptide hybrid (such as-W-PEG-X-PEG-Y. W, X, Y : different functional peptides) by conjugating different bioactive peptides with PEG. As a first step for preparation of a multifunctional PEG hybrid, we were successful in preparing bifunctional peptide-PEG hybrids [X-PEG-Y (X, Y : different bioactive peptides)] using an amino acid type PEG (aaPEG) which was prepared from a commercially available PEG in our laboratory. RGD-PEG-EILDV and PDSGR-PEG-YIGSR were prepared and they showed antimetastatic activity.
|
